Neurofibrillary tangles (NFTs), composed of truncated and hyperphosphorylated tau, are a common feature of numerous agingrelated neurodegenerative diseases, including Alzheimer's disease (AD). However, the molecular mechanisms mediating tau truncation and aggregation during aging remain elusive. Here we show that asparagine endopeptidase (AEP), a lysosomal cysteine proteinase, is activated during aging and proteolytically degrades tau, abolishes its microtubule assembly function, induces tau aggregation and triggers neurodegeneration. AEP is upregulated and active during aging and is activated in human AD brain and tau P301S-transgenic mice with synaptic pathology and behavioral impairments, leading to tau truncation in NFTs. Tau P301S-transgenic mice with deletion of the gene encoding AEP show substantially reduced tau hyperphosphorylation, less synapse loss and rescue of impaired hippocampal synaptic function and cognitive deficits. Mice infected with adeno-associated virus encoding an uncleavable tau mutant showed attenuated pathological and behavioral defects compared to mice injected with adeno-associated virus encoding tau P301S. Together, these observations indicate that AEP acts as a crucial mediator of tau-related clinical and neuropathological changes. Inhibition of AEP may be therapeutically useful for treating tau-mediated neurodegenerative diseases. npg
a r t i c l e s AD is a progressive neurodegenerative disease characterized by two neuropathological hallmarks: extracellular senile plaque deposits, composed of amyloid beta (Aβ), and intracellular NFTs, made of truncated and hyperphosphorylated tau. Tau-mediated neurodegeneration may result from the combination of toxic gains of function acquired by the aggregates and the detrimental effects that arise from the loss of the normal functions 1 . Tau is mainly expressed in neurons and abundant in the neuronal axons, regulating microtubule (MT) polymerization and stabilizing MTs. Through alternative splicing, the MAPT gene yields six major isoforms of tau 2 . Whereas normal phosphorylation of tau controls the dynamics of MT, establishing neuronal polarity, axonal outgrowth and axonal transport [3] [4] [5] [6] , pathological hyperphosphorylation in disease severely interferes with tau's ability to regulate MT dynamics [7] [8] [9] . Hyperphosphorylated tau displays an increased propensity to form paired helical filaments (PHFs) in vitro and sequesters full-length tau and other MT-associated proteins [10] [11] [12] , indicating that hyperphosphorylation is a potent inducer of tau pathology. In AD, tau undergoes a number of other post-translational modifications in addition to phosphorylation that contribute to the tau aggregation and disease pathology.
Tau is a substrate for various proteases. It can be cleaved by several caspases at D421. In AD brain, tau truncated at Asp421 is a component of NFTs, and Aβ induces this cleavage in cultured neurons [13] [14] [15] . In AD brain, calpain 1 and calpain 2 are abnormally activated 16 . Aβ treatment leads to activation of calpains and production of a 17-kDa fragment in neurons (tau 45−230 ). Overexpression of tau 45−230 induces neuronal apoptosis 17 . In addition to caspases and calpains, thrombin and cathepsins have also been implicated in processing tau [18] [19] [20] . However, many tau fragments found in AD are not well characterized, and the proteases responsible for their generation have not all been identified. For instance, a tau fragment of 25-35 kDa in the cerebrospinal fluid (CSF) has been used as an early marker of AD 21, 22 , but the proteases responsible for this cleavage event are unknown.
Mammalian AEP, also known as legumain (LGMN), is a lysosomal cysteine protease that cleaves protein substrates on the C-terminal side of asparagine 23, 24 . AEP activation is autocatalytic and requires sequential removal of C-and N-terminal propeptides at different pH thresholds 25 . Recently, we showed that neuronal AEP is involved in neuronal apoptosis through its degradation of the DNase inhibitor SET during excitoneurotoxicity 26 and that AEP cleaves TDP-43 in post-mortem brain from humans with frontotemporal lobar degeneration 27 . In this report, we show that AEP cleaves tau at both N255 and N368 residues, induces tau aggregation and attenuates its MT-stabilizing activity. Furthermore, AEP is highly activated in tau P301S-transgenic mice and human AD brains. Consistent with this, an AEP-cleaved tau fragment at N368 is detected in human AD brains. Knockout of AEP in tau P301S mice leads to a reduction of tau hyperphosphorylation, protecting against memory loss. Blockade of tau cleavage by AEP rescues tau P301S-triggered pathological and behavioral defects. Hence, our results suggest that tau is a physiological substrate of AEP and that AEP is a mechanism-based therapeutic target for treating tauopathies including AD.
RESULTS

AEP directly cleaves tau
To explore whether AEP proteolytically processes tau, we conducted an in vitro cleavage assay with kidney lysates prepared from wild-type (Lgmn +/+ ) and Lgmn-knockout (Lgmn −/− ) mice under pH 7.4 or 6.0. At pH 6.0, AEP was active, cleaving tau into two fragments, whereas at pH 7.4 AEP was inactive ( Fig. 1a) . AEP enzymatic activity in kidney lysates was confirmed by an activity assay ( Fig. 1a) . When cotransfected with GST-tau, wild-type AEP strongly triggered tau fragmentation, whereas AEP proteins with mutations that abolish the cysteine protease activity of AEP (C189S) or the zymogen autocleavage required for its activation (N323A) 25 were unable to provoke tau cleavage, indicating AEP is responsible for eliciting tau proteolytic cleavage ( Fig. 1b) . Furthermore, the peptide inhibitor AENK completely suppressed tau cleavage by AEP, whereas the inactive control AEQK had no effect ( Fig. 1c) .
A selective anti-AEP antibody also attenuated tau fragmentation ( Fig. 1d ), suggesting that tau can be specifically cleaved in an AEPdependent manner. A biochemical assay with purified active AEP and recombinant GST-tau revealed that purified AEP indeed potently and directly cleaved tau ( Fig. 1e) . Moreover, tau was degraded in both Lgmn +/+ and Lgmn +/− mice at pH 6.0, but this effect was substantially attenuated in Lgmn −/− mice. By contrast, at pH 7.4, where AEP is inactive, tau remained intact regardless of AEP genotypes (Fig. 1f) . AEP enzymatic activities were also validated by fluorescent substrate cleavage assay ( Fig. 1g) . Together, these results strongly support that tau is a direct substrate of AEP.
AEP cleaves endogenous tau at N255 and N368
To identify the AEP cleavage sites on tau, we purified the fragmented GST-tau proteins with molecular weights of approximately 50 and 60 kDa and performed mass spectrometry analysis ( Fig. 2a) . We identified two partial-tryptic peptides ending with N255 and N368 from LC-MS/MS (Fig. 2b) . The amino acid number is based on the longest tau isoform (isoform 2, amino acids 1-441). To avoid unnecessary confusion, we adopted isoform 2's numbering system, though we employed isoform 4 (amino acids 1-352) in all of our in vitro experiments. Mutation of tau to either N368A or N255A blocked the appearance of the band at 60 kDa or 50 kDa, respectively ( Fig. 2c) the presence of active AEP ( Fig. 2c ), suggesting that N255 and N368 are the two major AEP cleavage sites on tau.
Moreover, we identified peptide N368 in human AD brain samples by mass spectrometry (Fig. 2d ), suggesting that tau cleavage at N368 by AEP occurs in human AD brain. Finally, we identified both N255 and N368 peptides in whole mouse brain extracts, and comparative label-free proteomic analysis revealed >20-fold enrichment for both N368 and N255 in Lgmn +/+ versus Lgmn −/− brain extracts ( Fig. 2e) . Hence, tau is a physiological substrate of AEP, which cleaves tau at both N255 and N368 sites.
AEP cleaves tau independent of caspases or calpains
Tau can be proteolytically processed by numerous proteinases including caspases, calpains, cathepsins, thrombin and puromycinsensitive aminopeptidase (PSA) 28 . We assessed the effect of their specific inhibitors on the processing of tau by AEP and found that tau cleavage was selectively reduced by the specific AEP inhibitor AENK but not by any of the other protease inhibitors ( Supplementary  Fig. 1a ). Remarkably, taus with point mutations of the cleavage sites of various proteases (R155A and K257A for thrombin; M419A for cathepsin; D421E for caspase-3; L43A/V229A for calpain) were prominently fragmented by active AEP, whereas the AEP mutant (N255A/N368A) remained intact ( Supplementary Fig. 1b) . These results indicate that cleavage by other proteases is not necessary for AEP processing of tau.
On the other hand, calpain cleavage analysis revealed that tau wildtype, N255A/N368A mutant and tau fragment (1-255) were cleaved in a time-dependent manner with consistent rates ( Supplementary  Fig. 1c ), indicating that AEP cleavage of tau does not affect proteolytic processing by calpains. We made a similar observation with both (e) Representative extracted ion chromatograms for tau N255 and N368 peptides from wild-type and Lgmn −/− mouse brain samples. Signal intensities were then normalized to wild-type samples, setting the maximum signal intensity to 100%. Values are represented as raw peptide extracted ion intensity. MS1 XIC, mass scan level 1, extracted ion chromatogram. All of the data represent two independent experiments. npg wild-type and tau N255A/N368A mutant in a caspase-3 cleavage assay ( Supplementary Fig. 1d ). Thus, AEP and other proteases can independently fragment tau. To test whether tau hyperphosphorylation influences tau cleavage by AEP, we pretreated GST-tau-transfected HEK293 cells with the protein phosphatase PP2 inhibitor okadaic acid and monitored tau fragmentation. GST-tau was cleaved in a time-dependent manner regardless of okadaic acid treatment ( Supplementary Fig. 1e,f) , indicating that hyperphosphorylation of tau does not interfere with AEP cleavage.
AEP is activated during the aging process and in human AD brains As age is the major risk factor for AD and the pH in the brain gradually decreases during aging 29, 30 , we sought to investigate tau degradation by AEP in the mouse brain at different ages. Tau was fragmented progressively with age, with degradation products detectable as early as 8 months of age ( Fig. 3a) . To further investigate tau fragmentation by AEP, we developed an anti-tau N368 antibody, which specifically recognized the cleaved tau 1-368 band but not full-length tau or tau 1-255 band ( Supplementary Fig. 2a,b) . The bands immunoprecipitated by anti-tau N368 antibody were recognized by two different tau-specific antibodies (tau1 and tau5), suggesting that AEP-cleaved tau but not other proteins was selectively immunoprecipitated (Supplementary Fig. 2c ). We detected tau immunoreactive fragments in 8-and 13-month-old mouse brains with anti-tau N368 (Fig. 3a) .
In agreement with this finding, we found that AEP activity also increased with aging, correlating with the tau cleavage pattern (Fig. 3b) . The tau fragmentation was completely abolished in Lgmn −/− brain, supporting the idea that tau degradation during aging is mediated by AEP (Fig. 3c) . The anti-tau N368 antibody also robustly labeled tau N368 immunoreactivity in human AD brain sections, whereas the signals were markedly attenuated in age-matched control brains ( Fig. 3d) . Preincubation with the antigen peptide (tau 360-368) abolished immunoreactivity ( Supplementary Fig. 2d ), supporting the specificity of the anti-tau N368 antibody. Furthermore, we found that tau N368 immunoreactive fragments were abundant in human AD brains but barely detectable in controls ( Fig. 3e) . Moreover, immunofluorescence staining revealed that tau N368 colocalized with thioflavin S-positive NFTs in human AD brains (Fig. 3f) , and tau N368 also colocalized with phosphorylated tau (Supplementary Fig. 2e ), indicating that AEP-induced fragments of tau are constituents of npg a r t i c l e s NFTs in vivo. AEP enzymatic activities in human AD brains were also higher than in controls ( Fig. 3g) , fitting with the marked tau N368 fragmentation in human AD samples. Further, AEP activity was elevated in tau P301S-transgenic mice compared to in age-matched control nontransgenic mice (Fig. 3h) . As expected, the pH in the transgenic mice brain cortex and hippocampus was lower compared to in nontransgenic controls (Fig. 3i) . Hence, AEP is activated in aging mouse brain, and it is also activated in both human AD brains and tau P301S-transgenic mice. Noticeably, Aβ oligomers elicited both AEP and tau fragmentation in a dose-dependent manner in primary rat neuronal cultures ( Supplementary Fig. 3a,b) . AEP was dose-dependently activated by Aβ, whereas cathepsin B, an AEP-related cysteine protease, was not activated. As expected, caspase-3 activity increased with Aβ in a concentration-dependent manner (Supplementary Fig. 3c-e) . Moreover, overexpression of AEP in primary neurons elicited demonstrable tau N368 degradation (Supplementary Fig. 3f ). Thus, Aβ may provoke AEP activation, resulting in tau degradation at N368.
AEP cleavage of tau generates neurotoxic fragments
To assess whether AEP cleavage may affect the functions of tau in promoting MT polymerization, we conducted an in vitro MT polymerization assay with purified tubulin in the presence of His-tagged tau fragments. As expected, full-length tau strongly augmented MT polymerization; in contrast, the stimulatory effects of truncated tau fragments 1-368 and 256-441 were greatly reduced. Although tau fragment 256-368 moderately increased MT polymerization in vitro, tau fragments 1-255 and 369-441 failed to induce polymerization (Fig. 4a-c) . Accordingly, overexpression of full-length tau in primary neurons notably increased axon length; in contrast, axon elongation was not enhanced in neurons expressing any one of the tau fragments (Fig. 4d) .
In neurons transfected with a mixture of the tau fragments, apoptosis was increased more than 60% compared to neurons transfected with full-length tau (Fig. 4e) . TUNEL staining showed that the tau fragments 1-368 and 256-368 triggered substantial apoptosis compared to wild-type or other tau fragments (Fig. 4f) . These results were confirmed in neurons infected with adeno-associated viruses (AAVs) encoding full-length tau or tau 1-368 ( Supplementary Fig. 4a,b) . Hence, tau fragments that lack the C-terminal tail after the N368 residue are neurotoxic. Furthermore, inhibitors of cyclin-dependent kinase 5, glycogen synthase kinase 3 and protein kinase (roscovitine, SB216763 and H89, respectively) did not attenuate the toxic effect of tau 1-368, indicating the neurotoxic effect of tau 1-368 is not dependent on its phosphorylation (Fig. 4g) .
AEP-generated tau fragments form insoluble fibrils in vitro
To investigate the effect of AEP cleavage on tau fragment propensity for filament formation, we monitored accumulation of PHFs using purified His-tagged tau recombinant proteins using a thioflavin S fluorescence assay. The tau fragment 256-368 displayed the strongest effect on self-assembly into filamentous structures, followed by the tau 1-368 and tau 256-441, and these fragments all exhibited a greater ability to form PHFs than full-length tau ( Supplementary  Fig. 5a) . Notably, tau 1-255 and tau 369-441 fragments were unable to aggregate into PHFs, whereas the mixture of these aforementioned fragments demonstrated an increased propensity to form PHFs (Supplementary Fig. 5a ). Consistent with the results of the thioflavine S assay, PHFs were observed under negative stain electron npg microscopy in samples prepared with tau fragments 1-368, 256-368, 256-441 and full-length tau. Again, a mixture of all of these fragments also formed filamentous structures (Supplementary Fig. 5b) . Fractionation of heparin-induced insoluble tau fibrils via ultracentrifugation revealed similar results, with tau fibrils of 256-368, 256-441 and 1-368 displaying the most robust aggregates, followed by fulllength tau (Supplementary Fig. 5c ). Hence, AEP processing of tau promotes its assembly into filaments.
To explore whether AEP-cleaved tau fragments induce tau phosphorylation, we transfected primary neurons with HA-tagged tau 1-255 or tau 1-368 and performed immunofluorescent staining with a monoclonal antibody, AT8, which recognizes tau protein phosphorylated at both S202 and T205. Overexpression of either tau fragment from AEP fragmentation elicited robust AT8 immunoreactivity, whereas full-length tau displayed no signal above endogenous levels (Supplementary Fig. 6) . Conceivably, AEP cleaves tau on both N255 and N368 sites, and the resultant fragments elicit tau hyperphosphorylation and aggregation.
Knockout of AEP prevents cognitive deficits in tau P301S mice
To assess the physiological role of AEP in synaptic function and behavior, we bred Lgmn −/− mice with tau P301S-transgenic mice to knock out Lgmn in tau P301S-transgenic mice. The genotypes of transgenic mice were validated (Supplementary Fig. 7) . Immunoreactivity for the tau N368 fragment was evident in tau P301S-transgenic mice but was not detectable in tau P301S/Lgmn −/− mice (Fig. 5a) . We confirmed the absence of tau N368 in tau P301S/Lgmn −/− mice by immunohistochemistry (Fig. 5b) . We found a ~30% reduction of AT8-and AT100-positive neurons in tau P301S/Lgmn −/− mice compared to tau P301S-transgenic mice both in the hippocampus and cortex ( Fig. 5c  and Supplementary Fig. 8) . Electron microscope analysis of brain sections showed that at 6 months of age, tau P301S-transgenic mice exhibited an overt reduction in synapses compared to wild-type and Lgmn −/− mice. Notably, tau P301S/Lgmn −/− mice showed greatly ameliorated synapse loss compared to tau P301S-transgenic mice ( Fig. 5d and Supplementary Fig. 9a ). Golgi staining revealed that Lgmn gene deletion prevented the loss of denritic spines in tau P301Stransgenic mice (Supplementary Fig. 9b,c) . Electrophysiological analysis found that the input/output (I/O) ratio was suppressed and the averaged field excitatory post-synaptic potential (fEPSP) slope was substantially reduced in tau P301S-transgenic mice compared to wild-type and tau P301S/Lgmn −/− mice (Supplementary Fig. 10a,b) , indicating that synaptic transmission is impaired in 6-month-old tau P301S-transgenic mice but rescued by Lgmn gene deletion. The npg a r t i c l e s paired-pulse ratios (induced by 100-and 200-ms intervals) were lower in tau P301S-transgenic mice but higher in wild-type and tau P301S/Lgmn −/− mice ( Fig. 5e ), suggesting an amelioration of presynaptic dysfunction due to Lgmn deletion. The long-term potentiation (LTP) of fEPSPs in the hippocampal CA1 region, which represents the molecular basis of learning and memory, was also diminished in tau P301S-transgenic mice compared with the control wild-type and tau P301S/Lgmn −/− mice (Fig. 5f) . Hence, knockout of Lgmn in tau P301S-transgenic mice substantially prevents the impairment in synaptic function caused by the tau mutation. Next, we assessed the effect of deleting the Lgmn gene on memory functions of tau P301S-transgenic mice in the Morris water maze. During the training phase, the swim distance and latency to find the platform were progressively decreased in the tau P301S-transgenic mice, demonstrating a learning effect, albeit they were substantially impaired compared to wild-type control or Lgmn −/− mice (Fig. 5g,h) . However, tau P301S/Lgmn −/− mice had greatly reduced learning deficits compared to tau P301S-transgenic mice (Fig. 5g,h) . A probe trail found that deletion of Lgmn in tau P301S-transgenic mice improved memory retention, as illustrated by the higher percentage of time spent in the target quadrant (Fig. 5i) . All groups of animals displayed comparable swim speeds (Fig. 5i) , indicating that the genetic manipulations did not have any deleterious effects on motor function.
Next, we conducted contextual and cued fear conditioning tests with these animals. Strikingly, tau P301S-transgenic mice displayed substantially lower levels of freezing compared to wild-type or Lgmn −/− mice (Fig. 5j) . Tau P301S/Lgmn −/− mice showed increased memory in both the cued fear test and the contextual fear assay compared to tau P301S-transgenic mice (Fig. 5j) . Therefore, deletion of Lgmn greatly reverses the spatial and associative learning deficits in tau P301S-transgenic mice.
Preservation of cognition in mice expressing uncleavable tau P301S
To confirm the effects of AEP are mediated via cleavage of tau, we injected AAVs encoding human tau P301S or tau P301S uncleavable by AEP (tau P301S/N255A/N368A) into the hippocampus of wild-type mice. Two months later, we detected similar levels of tau P301S and tau P301S/N255A/N368A in the hippocampus by immunohistochemistry and western blotting with the human tau-specific antibody HT-7 (Fig. 6a,b) . The density of synapse in the hippocampus of mice injected with AAV-tau P301S was substantially less than in mice injected with an AAV-GFP control. However, the synaptic density was preserved when the mice were injected with AAV-tau P301S/N255A/N368A (Fig. 6c,d) .
Electrophysiological analysis found that the paired-pulse ratios were lower in mice injected with AAVs encoding tau P301S compared with mice injected with control virus, indicating evident presynaptic dysfunction. The paired-pulse ratios were improved in mice injected with AAV-tau P301S/N255A/N368A compared to mice injected with AAV-tau P301S (Fig. 6e) . Notably, mice injected with AAV-tau P301S/ N255A/N368A showed improved LTP compared to mice injected with npg AAV-tau P301S (Fig. 6f) . The I/O curve shows that the averaged slope of fEPSPs is smaller in mice expressing tau P301S than in those expressing tau P301S/N255A/N368A (Fig. 6g,h) . These results indicate that the synaptic function is preserved in mice expressing noncleavable tau P301S.
In the Morris water maze test, tau P301S/N255A/N368A-expressing mice showed decreased latency to find the platform during the training phase and increased percentage of time in the target quadrant during the probe test compared to mice injected with AAV-tau P301S, indicating preserved cognitive function (Fig. 6i,j) . The preservation of synaptic and cognitive function by the mutation of AEP cleavage site indicates that the cleavage of tau is required for the effects of AEP.
DISCUSSION
In the present study, we have identified that AEP acts as a physiological protease that cleaves tau in an age-dependent manner in mouse and human brain, including in AD. AEP processes tau at both N255 and N368, inhibiting tau-mediated effects on MT assembly and axon elongation. The resultant C terminus-deleted tau fragments are prone to aggregation and strongly trigger neurodegeneration, indicating that AEP activation may induce neuronal cell death through proteolytic degradation of tau. These findings fit with the most recent report that AEP is activated in human AD brains and translocates from lysosomes into the cytoplasm 31 . Presumably, the cytoplasmic-translocated AEP cleaves tau, leading to disruption of MT dynamics, NFT formation and neurodegeneration. We noticed that the different pathogenic processes are not necessarily associated with the same AEP-derived fragment. However, the one AEP-derived fragment that does show some of the common toxic effects is tau 1-368. Our data also support that deletion of Lgmn from tau P301S-transgenic mice substantially decreases tau hyperphosphorylation and alleviates synaptic loss and memory deficit in the mice.
Previous studies in a transgenic (tau P301S) tauopathy mouse model revealed that synapse loss and microglial activation precede the appearance of NFTs, presumably owing to the impaired transport that results from tau hyperphosphorylation 32 . Here, we provide convergent biochemical and cellular evidence that suggests AEP cleavage of tau also contributes to synaptic loss in tau P301S-transgenic mice. Notably, tau hyperphosphorylation does not affect tau proteolytic degradation by AEP. Thus, although tau phosphorylation may prevent its cleavage by caspase-3 (ref. 33) , AEP cleavage of tau seems to be independent of phosphorylation. However, we found that truncation of tau by AEP facilitates tau hyperphosphorylation. Consistent with our findings, expression of truncated tau 151-391 in the brain of transgenic animals induces the complete tau cascade of neurofibrillary degeneration as found in humans 34 . Therefore, all these observations support truncation of tau as a key post-translational modification provoking neurofibrillary degeneration with pathological features similar to those found in human AD.
AEP levels increase in an age-dependent manner. As expected, tau is fragmented by AEP in mouse brain at the age of 8 months, when AEP expression is high. NFTs are the first pathology that occurs during aging and AD, and their burden correlates with the degree of cognitive impairment [35] [36] [37] , providing the initial circumstantial evidence to suggest that toxic gains of function by NFTs might play an important part in the progression of the disease. The reduction in the amount of hyperphosphorylated tau in tau P301S/Lgmn −/− mice compared to age-matched tau P301S-transgenic mice indicates AEP might act as a crucial protease triggering NFT pathology in AD during aging. Moreover, Lgmn knockout ameliorates synaptic loss, LTP impairment and memory loss in tau P301S-transgenic mice, supporting that AEP might be an upstream trigger in AD onset and progression. The preservation of synaptic and cognitive function in mice expressing tau P301S uncleavable by AEP further confirms that the effects of AEP are mediated by the cleavage of tau. Conceivably, blockade of this protease may provide an innovative therapeutic intervention for treating neurodegenerative diseases, including AD.
METHODS
Methods and any associated references are available in the online version of the paper.
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